Passive Immunity Trial for Our Neighbors (PassITON): A randomized, placebo-controlled multi-site trial of anti-SARS-CoV-2 convalescent plasma to treat hospitalized adults with COVID-19
- Funded by National Institutes of Health (NIH)
- Total publications:2 publications
Grant number: 3UL1TR002243-04S3
Grant search
Key facts
Disease
COVID-19Start & end year
20172022Known Financial Commitments (USD)
$34,000,000Funder
National Institutes of Health (NIH)Principal Investigator
Gordon R BernardResearch Location
United States of AmericaLead Research Institution
Vanderbilt University Medical CenterResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
Data Management and Data Sharing
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase III
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The Vanderbilt Institute for Clinical and Translational Research (VICTR) is a highly functionaland integrated clinical and translational (C&T) research infrastructure that has raised the qualityand scientific rigor of the research conducted at Vanderbilt and longstanding partner Meharry,the nation's oldest historically black academic health science institution. VICTR will contribute tothe mission of the CTSA program while leveraging unique resources and expertise withinVICTR's Hub with these aims: 1) Leverage VICTR's strong collaborative energy to enhanceteam science methodologies that propel transdisciplinary research approaches, and integrateproven community engagement principles to stakeholders for all stages of research; 2) Develop,implement and disseminate informatics and data organization methods to promulgate researchefficiency, quality, and preparedness and integrate data collection in the conduct of pragmatictrials; 3) Ensure the translational science workforce is diverse and has the skills, knowledge,and resources necessary to advance translation of discoveries; 4) Measurably improve theefficiency, quality, and representativeness of C&T studies by enhancing and systematicallyintegrating services and programs that support highest quality research initiation and conduct;5) Measurably improve the efficiency and quality of multi-site clinical trials, in collaboration withthe TICs and RICs, by leveraging centralized regulatory and legal agreements, providing rapidfeasibility and recruitment methods and practices, and creating and disseminating novel clinicaltrial designs and methodologies; and 6) Utilize unique strengths leveraging novel resourcesBioVU and PheWAS to guide drug development and repurposing.
Publicationslinked via Europe PMC
Last Updated:2 days ago
View all publications at Europe PMC